Frederick B. Oleson, Jr., D.Sc. has served as our Vice President, Non-Clinical Development since 1999. Previously, he served as Vice President, Drug Development / Preclinical Development from 1997-1999 and was Program Executive for an in-licensed program from 2002-2004. Prior to joining us, Dr. Oleson was an independent consultant from June 1997 to November 1997. From January 1997 to June 1997, Dr. Oleson served as Director of Preclinical Research at Autoimmune, Inc., a biotechnology company. From 1992 to January 1997, Dr. Oleson served as Director, Toxicology and Preclinical Pharmacology at Biogen, Inc. Dr. Oleson also held various positions at Bristol-Myers Squibb from 1983 to 1992, including Director, Investigative Toxicology from 1990-1992. Dr. Oleson was a key contributor in the development of the Biogen drug Avonex® and of Angiomax® for The Medicines Company. While at Cubist, he has had a major role in the development and marketing approval of CUBICIN®. Dr. Oleson received his B.S. in Biochemistry from Princeton University and a M.S. and D.Sc. in Physiology/ Radiation Biology from Harvard University School of Public Health.